A Phase 2, 16 Week, Multicenter, Randomized, Double Blind Placebo Controlled, Parallel Group Proof of Concept Study Evaluating the Efficacy and Safety of Tanezumab for the Treatment of Pain Associated With Endometriosis.
Phase of Trial: Phase II
Latest Information Update: 28 Apr 2010
At a glance
- Drugs Tanezumab (Primary)
- Indications Pain
- Focus Therapeutic Use
- Sponsors Pfizer
- 14 Apr 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 14 Apr 2010 Actual patient number (48) added as reported by ClinicalTrials.gov.
- 31 Mar 2010 Planned end date changed from 1 May 2010 to 1 Mar 2010 as reported by ClinicalTrials.gov.